RegulationPriority Review (China), Conditional marketing approval (China), Orphan Drug (European Union), Fast Track (United States), Accelerated Approval (United States)

Structure/Sequence

Molecular FormulaC17H11F6N7O

InChIKeyDEVSOMFAQLZNKR-RJRFIUFISA-N

CAS Registry1393477-72-9

211

Clinical Trials associated with Selinexor

NCT06822972

/ Not yet recruitingPhase 2IIT

A Phase II Safety and Efficacy Study of Selinexor in Combination With Bispecific Antibody in Patients With Relapsed/Refractory Multiple Myeloma

The primary objectives of this study are to determine the safety of single agent Selinexor given with commercial bispecific antibody therapy in patients with Relapsed/Refractory Multiple Myeloma (RRMM) and to determine the MRD negativity rate at 10-5 at 12 months post bispecific antibody therapy.
The investigators will enroll 27 patients with RRMM who are receiving commercial bispecific antibody therapy. Patients will be on treatment for 12 months or until disease progression, and will be followed for 24 months. Study assessments include completing a drug diary, having a safety check in call, and have history, clinical assessments, and labs taken.
Twenty-seven patients will provide 80% power in a one-sample chi square test for a proportion assuming that the rate of negative MRD at 10-5 at 12 months post bispecific antibody therapy is 25% in historical control and 50% in the SEL+bispecific antibody experimental treatment group, under a one-sided 5% significance level.

Start Date01 May 2025

Sponsor / Collaborator

Duke University

NCT06853678

/ RecruitingNot ApplicableIIT

Selinexor Combined With Nab-paclitaxel and Adebrelimab as Second-line Treatment for ES-SCLC：A Prospective, Single-center, Single-arm Clinical Study

At present, the first-line standard treatment for patients with extensive-stage small cell lung cancer (ES-SCLC) is immunotherapy combined with chemotherapy. For patients who relapse within 6 months after first-line chemotherapy, conventionally recommended chemotherapy drugs include topotecan, irinotecan, gemcitabine, paclitaxel or vinorelbine, etc., but due to limited benefits to patients, patients are also recommended to participate in relevant clinical studies. New treatment methods are constantly being explored in second-line treatment, including fluzoparib combined with adebelimumab. The current status of second-line treatment is still worrying.
Selinexor is a class of nuclear export selective inhibitors (SINEs) for the export protein receptor XPO1. PO1 promotes the transport of mRNA and cargo proteins, including tumor suppressor proteins (TSPs), hormone receptors (GRs), and immune response regulators. Selinexor covalently binds to the XPO1 protein, blocking the export of TSPs and GRs and accumulating them in the nucleus, preventing the translation of oncoprotein mRNA, stopping the cell cycle process, and initiating apoptosis. Multiple in vitro and in vivo studies have verified that selinexor combined with chemotherapy/radiotherapy/targeted therapy exhibits significant anti-tumor activity.
This study plans to use selinexor combined with adebrelimab and albumin-paclitaxel as a second-line treatment for ES-SCLC to explore the efficacy and safety of this regimen.

Start Date28 Feb 2025

Sponsor / Collaborator

Tianjin Medical University Cancer Institute and Hospital

NCT06813079

/ Not yet recruitingPhase 2IIT

ADOPT: Adaptive Organoid-Based Precision Therapy Study in Pancreatic Cancer - A Prospective Single-Arm Phase II Trial

The purpose of this study is to see if using Patient Derived Organoids (PDO) to choose a drug for the treatment of pancreatic cancer individually for each patient is useful. The study will look at the number of participants who have a response to their assigned drug.

Start Date17 Feb 2025

Sponsor / Collaborator

University Health Network

100 Clinical Results associated with Selinexor

100 Translational Medicine associated with Selinexor

100 Patents (Medical) associated with Selinexor

720

Literatures (Medical) associated with Selinexor

01 Dec 2025·Molecular Biology Reports

Prognostic and functional role of the nuclear export receptor 1 (XPO1) in gastrointestinal cancers: a potential novel target?

Review

Author: Gruber, Rebecca ; Sokolova, Viktorija ; Klieser, Eckhard ; Amann, Arno ; Ormanns, Steffen ; Günther, Michael ; Seeber, Andreas ; Pichler, Renate ; Neureiter, Daniel ; Pammer, Lorenz M ; Kocher, Florian

In the last decades the survival of metastatic gastrointestinal (GI) cancer patients could have been significantly extended due to the introduction of targeted- and immunotherapy. However, only the minority of patients will experience long-lasting survival. Hence, novel therapeutics are clearly necessary for GI cancer patients. Molecular high-throughput profiling techniques have revealed potential novel targetable molecular alterations, emphasizing the necessity for tailored therapeutic approaches. Nuclear export proteins, particularly Exportin-1 (XPO1), have emerged as promising targets in cancer therapy due to their crucial role in cellular homeostasis and regulation of key cellular functions. Dysregulation of XPO1-mediated nuclear export leads to the functional loss of tumor suppressors and pro-apoptotic factors, facilitating cancer progression. Selinexor, a XPO1 inhibitor, has shown promising activity in preclinical and clinical studies, particularly in hematological malignancies. However, its efficacy in GI cancers remains underexplored. This review aims to elucidate the functional and pathophysiological role of XPO1 in GI cancers. Despite the potential of XPO1 inhibitors in suppressing cell proliferation and inducing apoptosis, comprehensive molecular landscape data and validation of selective inhibitors in GI cancers are lacking. Targeting XPO1 presents a significant therapeutic potential for the treatment of GI cancer patients. Further research is necessary to fully elucidate the molecular landscape according to XPO1 expression in GI tumors and to validate the efficacy of selective XPO1 inhibitors. These efforts are expected to contribute to the development of more effective and personalized therapeutic strategies for GI cancer patients.

01 Apr 2025·Recent Patents on Anti-Cancer Drug Discovery

Selinexor as a Therapeutic Target: Advances in Non-small Cell and Small Cell Lung Cancer Treatment Strategies

Article

Author: Liu, Qingyi ; Xie, Shaonan ; Wang, Shize ; Liu, Yanjie ; Zhang, Wenqi ; Zheng, Bosheng ; Liu, Guangjie ; Gao, Maogang ; Han, Yaqing

Selinexor treats lung cancer, particularly non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). This review summarizes the prevalence and types of lung cancer and emphasizes the challenges associated with current treatments like resistance and limited effectiveness. Selinexor is a selective inhibitor of nuclear export (SINE) that has emerged as a potential therapy that targets the nuclear export of tumor suppressor proteins. The mechanisms of selinexor, its potential in combination therapies, and challenges like side effects and drug resistance are explained in this review. Key findings highlight the effectiveness of selinexor in preclinical studies, particularly against KRAS-mutant NSCLC and in combination with chemotherapy for SCLC. The review concludes with a discussion of future directions and underscores the potential of selinexor to improve the treatment strategies for lung cancer.

01 Mar 2025·Cancer Letters

Atovaquone and selinexor as a novel combination treatment option in acute myeloid leukemia

Article

Author: Stoiber, Dagmar ; Edtmayer, Sophie ; Heindl, Kerstin ; Weiss, Stefanie ; Zdársky, Bernhard ; Podar, Klaus ; Witalisz-Siepracka, Agnieszka ; Casanova, Emilio ; Holzer, Anja

Acute myeloid leukemia (AML) is the most common acute leukemia and is predominantly affecting the elderly. It is a heterogenous disease, showing a broad spectrum of genomic alterations and mutations that influence the clinical outcome and treatment options. The expression of the signal transducer and activator of transcription 3 (STAT3) is often dysregulated in AML and its constitutive activation is associated with poor outcome. Thus, STAT3 became an attractive therapeutic target but until now drugs targeting STAT3 only had moderate efficacy. This phenomenon might be related to the expression ratio of the two alternatively spliced isoforms: the full-length isoform STAT3α and the truncated version STAT3β, which play opposite roles in AML. In this study, we investigated the potential of selected, well-established drugs to impact the STAT3β/α ratio, as a higher STAT3β/α ratio is associated with better disease outcome. Atovaquone and selinexor independently elevated the STAT3β/α ratio and led to an upregulation of the STAT3β target gene SELL (CD62L). The combined treatment with atovaquone and selinexor entailed synergistic killing of AML cells in vitro and impaired the leukemic cell infiltration in vivo. Moreover, CD62L overexpression in a human AML cell line resulted in significantly prolonged survival in a xenograft mouse model. We propose that targeting the STAT3β/α ratio could be a promising new strategy for treating patients with AML and that the combination of selinexor and atovaquone could offer enhanced treatment outcomes.

245

News (Medical) associated with Selinexor

05 Mar 2025

·www.prnewswire.com

XPOVIO® (selinexor) Approved for Commercialization in Indonesia, Further Expanding Antengene's Commercial Presence in APAC

- XPOVIO® is the first and only approved XPO1 inhibitor in Indonesia. - From the second half of 2024 to now, XPOVIO® was successively approved in Thailand, Malaysia and Indonesia, significantly expanding Antengene's commercial presence in APAC. To date, XPOVIO® has been approved for multiple indications in ten markets across the APAC region. - XPOVIO® has been approved for health insurance coverage in the mainland of China, Taiwan market, Australia, Singapore and South Korea. SHANGHAI and HONG KONG, March 5, 2025 /PRNewswire/ -- Antengene Corporation Limited ( "Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for cancer, today announced that the Indonesia National Agency of Drug and Food Control (BPOM) has approved a New Drug Application (NDA) for XPOVIO® (selinexor) for three indications: (1) In combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma (MM) who have received at least one prior therapy;(2) in combination with dexamethasone for the treatment of adult patients with relapsed or refractory MM (R/R MM) who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors (PIs), at least two immunomodulatory agents (IMiDs), and an anti‐CD38 monoclonal antibody; and (3) as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B‐cell lymphoma (R/R DLBCL), not otherwise specified, including DLBCL arising from follicular lymphoma, after at least two lines of systemic therapy who are not eligible for haematopoietic cell transplant. With a novel mechanism of action, XPOVIO® is the world's first approved orally-available, selective XPO1 inhibitor, which has already been approved in ten countries and regions in APAC, and has been included in the national insurance schemes in five of these markets (the mainland of China, Taiwan market, Australia, Singapore and South Korea). The ASEAN region, with its steady economic growth and a population exceeding 600 million, has become a market of significant potential for global biomedical development. The accelerating aging population in ASEAN has increased the overall disease burden on patients and local communities, leading to a growing demand for novel therapeutics. Currently, Antengene is actively expanding its presence into APAC markets in efforts to introduce more innovative medicines to the ASEAN region in the future, improving the level of healthcare in these regions and benefiting more patients in need. While bringing XPOVIO® to more APAC markets, Antengene is also striving to expand the indications of XPOVIO®. Leveraging the drug's novel mechanism of action, Antengene is currently developing multiple combination regimens of XPOVIO® for the treatment of various indications including myelofibrosis (MF) and endometrial cancer. About XPOVIO® (selinexor) XPOVIO® is the world's first approved orally-available, selective inhibitor of the nuclear export protein XPO1. It offers a novel mechanism of action, synergistic effects in combination regimens, fast onset of action, and durable responses. By blocking the nuclear export protein XPO1, XPOVIO® can promote the intranuclear accumulation and activation of tumor suppressor proteins and growth regulating proteins, and down-regulate the levels of multiple oncogenic proteins. XPOVIO® delivers its antitumor effects through three mechanistic pathways: 1) exerting antitumor effects by inducing the intranuclear accumulation of tumor suppressor proteins; 2) reducing the level of oncogenic proteins in the cytoplasm by inducing the intranuclear accumulation of oncogenic mRNAs; 3) restoring hormone sensitivity by activating the glucocorticoid receptors (GR) pathway. To utilize its unique mechanism of actions, XPOVIO® is being evaluated for use in multiple combination regimens in a range of indications. At present, Antengene is conducting multiple clinical studies of XPOVIO® in the mainland of China for the treatment of relapsed/refractory hematologic malignancies and solid tumors (3 of these studies are being jointly conducted by Antengene and Karyopharm Therapeutics Inc. [Nasdaq:KPTI]). About Antengene Antengene Corporation Limited ( "Antengene", SEHK: 6996.HK) is a leading commercial-stage R&D-driven global biopharmaceutical company focused on the discovery, development, manufacturing and commercialization of innovative first-in-class/best-in-class therapeutics for the treatment of hematologic malignancies and solid tumors, in realizing its vision of "Treating Patients Beyond Borders". Since 2017, Antengene has built a pipeline of 9 oncology assets at various stages going from clinical to commercial, including 6 with global rights, and 3 with rights for the APAC region. To date, Antengene has obtained 31 investigational new drug (IND) approvals in the U.S. and Asia, and submitted 10 new drug applications (NDAs) in multiple Asia Pacific markets, with the NDA for XPOVIO® (selinexor) already approved in Mainland of China, Taiwan China, Hong Kong China, Macau China, South Korea, Singapore, Malaysia, Thailand, Indonesia and Australia. Forward-looking statements The forward-looking statements made in this article relate only to the events or information as of the date on which the statements are made in this article. Except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. You should read this article completely and with the understanding that our actual future results or performance may be materially different from what we expect. In this article, statements of, or references to, our intentions or those of any of our Directors or our Company are made as of the date of this article. Any of these intentions may alter in light of future development. For a further discussion of these and other factors that could cause future results to differ materially from any forward-looking statement, please see the other risks and uncertainties described in the Company's Annual Report for the year ended December 31, 2023, and the documents subsequently submitted to the Hong Kong Stock Exchange. For more information, please contact: Investor Contacts: Donald Lung E-mail: [email protected] Mobile: +86 18420672158 PR Contacts: Peter Qian E-mail: [email protected] Mobile: +86 13062747000 SOURCE Antengene Corporation Limited WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Drug ApprovalNDA

05 Mar 2025

·www.pharmaceutical-technology.com

Indonesia approves Antengene’s Xpovio NDA for multiple indications

Several clinical studies of the therapy are underway in mainland China. Credit: Chay_Tee/Shutterstock. Antengene’s new drug application (NDA) for Xpovio (selinexor) has gained approval from the Indonesia National Agency of Drug and Food Control for three indications. The approval paves the way for Xpovio to be used in conjunction with other therapies and as a monotherapy in specific cancer treatments. The approval for the indications is in conjunction with bortezomib and dexamethasone for treating adults with multiple myeloma (MM) who have undergone a minimum of one previous treatment. Xpovio can also be used as a single agent to treat adults with relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL), including DLBCL which arises from follicular lymphoma, after a minimum of two systematic therapy lines. Xpovio with dexamethasone is approved for treating adults with R/R MM who have undergone at least four previous therapies and whose disease is refractory to a minimum of two proteasome inhibitors (PIs), two immunomodulatory agents (IMiDs) and an anti‐cluster of differentiation 38 (CD38) monoclonal antibody. With this new approval, the therapy extends its reach in the Asia Pacific (APAC) region, in which it has already been approved in 10 nations and included in national insurance schemes in five markets. Antengene is currently working on broadening the therapy’s presence, aiming to introduce more medicines to the Association of Southeast Asian Nations (ASEAN) region. The company is focused both on widening the market reach of Xpovio and on expanding its indications. It is exploring several combo regimens of the therapy for conditions including myelofibrosis and endometrial cancer. Several clinical studies are underway in mainland China to evaluate Xpovio in treating relapsed/refractory haematologic malignancies and solid tumours. Three of these are being conducted jointly by Antengene and Karyopharm Therapeutics. In July 2024, China’s National Medical Products Administration approved Xpovio as a monotherapy for treating adults with R/R DLBCL.

Drug ApprovalImmunotherapy

24 Feb 2025

·www.prnewswire.com

Karyopharm Announces 1-for-15 Reverse Stock Split

NEWTON, Mass., Feb. 24, 2025 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that it will implement a 1-for-15 reverse stock split of the issued shares of the Company's common stock ("Reverse Stock Split"), effective at 5:00 p.m. Eastern Time on February 25, 2025. The Reverse Stock Split was approved by the Company's stockholders at the Company's Special Meeting of Stockholders held on January 30, 2025, with the final ratio subsequently determined by the Company's Board of Directors. One of the primary goals of the Reverse Stock Split is to increase the per-share market price of the Company's common stock to enable the Company to regain compliance with the minimum bid price requirement for continued listing on the Nasdaq Global Select Market. The Company's common stock is expected to begin trading on a split-adjusted basis when the markets open on February 26, 2025 under the Company's existing trading symbol "KPTI" with the new CUSIP number 48576U 205. At the effective time of the Reverse Stock Split, every 15 shares of the Company's issued and outstanding common stock will be automatically reclassified and combined into 1 share of common stock. This will reduce the number of issued and outstanding shares of common stock from approximately 126.2 million shares to approximately 8.4 million shares. The Reverse Stock Split will proportionately reduce the number of authorized shares of the Company's common stock from 800,000,000 shares to 53,333,333 shares. In addition, proportionate adjustments will be made to the number of shares of common stock available for issuance under the Company's equity incentive plans; the number of shares underlying, and the exercise prices of, outstanding equity awards under such plans and outstanding warrants; and the conversion rates of outstanding convertible notes, in accordance with their respective terms and as described in the Company's proxy statement for the Special Meeting of Stockholders as filed with the Securities and Exchange Commission on December 16, 2024 (the "Proxy Statement"). No fractional shares will be issued, if, as a result of the Reverse Stock Split, a stockholder would otherwise become entitled to a fractional share because the number of shares of common stock they hold before the Reverse Stock Split is not evenly divisible by the split ratio. Instead, each stockholder will be entitled to receive a cash payment in lieu of a fractional share. Computershare Trust Company, N.A., is acting as the exchange agent and transfer agent for the Reverse Stock Split. Stockholders holding their shares electronically are not required to take any action to receive post-split shares. Stockholders owning shares through a bank, broker or other nominee will have their positions adjusted to reflect the Reverse Stock Split and will receive payment for any fractional shares in accordance with their respective bank's, broker's, or nominee's particular processes. Additional information about the Reverse Stock Split can be found in the Proxy Statement and on the Company's Investor Relations website at . About Karyopharm Therapeutics Karyopharm Therapeutics Inc. (Nasdaq: KPTI) is a commercial-stage pharmaceutical company whose dedication to pioneering novel cancer therapies is fueled by a belief in the extraordinary strength and courage of patients with cancer. Since its founding, Karyopharm has been an industry leader in oral compounds that address nuclear export dysregulation, a fundamental mechanism of oncogenesis. Karyopharm's lead compound and first-in-class, oral exportin 1 (XPO1) inhibitor, XPOVIO® (selinexor), is approved in the U.S. and marketed by the Company in three oncology indications. It has also received regulatory approvals in various indications in a growing number of ex-U.S. territories and countries, including Europe and the United Kingdom (as NEXPOVIO®) and China. Karyopharm has a focused pipeline targeting indications in multiple high unmet need cancers, including in multiple myeloma, endometrial cancer, myelofibrosis, and diffuse large B-cell lymphoma (DLBCL). For more information about our people, science and pipeline, please visit , and follow us on LinkedIn and on X at @Karyopharm. Forward-Looking Statements This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Such forward-looking statements include those regarding the Reverse Stock Split and authorized share reduction and the timing thereof; the impact of the Reverse Stock Split and authorized share reduction on stockholders; the potential impact of the Reverse Stock Split on the Company's share price; and the potential for the Company to regain compliance with the minimum bid price requirement for continued listing on the Nasdaq Global Select Market. Such statements are subject to numerous important factors, risks and uncertainties, many of which are beyond Karyopharm's control, that may cause actual events or results to differ materially from Karyopharm's current expectations. For example, there can be no guarantee that Karyopharm will successfully commercialize XPOVIO or that any of Karyopharm's drug candidates, including selinexor, will successfully complete necessary clinical development phases or that development of any of Karyopharm's drug candidates will continue. Further, there can be no guarantee that any positive developments in the development or commercialization of Karyopharm's drug candidate portfolio will result in stock price appreciation. Management's expectations and, therefore, any forward-looking statements in this press release could also be affected by risks and uncertainties relating to a number of other factors, including the following: the adoption of XPOVIO in the commercial marketplace, the timing and costs involved in commercializing XPOVIO or any of Karyopharm's drug candidates that receive regulatory approval; the ability to obtain and retain regulatory approval of XPOVIO or any of Karyopharm's drug candidates that receive regulatory approval; Karyopharm's results of clinical trials and preclinical trials, including subsequent analysis of existing data and new data received from ongoing and future trials; the content and timing of decisions made by the U.S. Food and Drug Administration and other regulatory authorities, investigational review boards at clinical trial sites and publication review bodies, including with respect to the need for additional clinical trials; the ability of Karyopharm or its third party collaborators or successors in interest to fully perform their respective obligations under the applicable agreement and the potential future financial implications of such agreement; Karyopharm's ability to enroll patients in its clinical trials; unplanned cash requirements and expenditures; substantial doubt exists regarding Karyopharm's ability to continue as a going concern; development or regulatory approval of drug candidates by Karyopharm's competitors for products or product candidates in which Karyopharm is currently commercializing or developing; the direct or indirect impact of the COVID-19 pandemic or any future pandemic on Karyopharm's business, results of operations and financial condition; and Karyopharm's ability to obtain, maintain and enforce patent and other intellectual property protection for any of its products or product candidates. These and other risks are described under the caption "Risk Factors" in Karyopharm's Annual Report on Form 10-K for the year ended December 31, 2024, which was filed with the Securities and Exchange Commission (SEC) on February 19, 2025, and in other filings that Karyopharm may make with the SEC in the future. Any forward-looking statements contained in this press release speak only as of the date hereof, and, except as required by law, Karyopharm expressly disclaims any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise. XPOVIO® and NEXPOVIO® are registered trademarks of Karyopharm Therapeutics Inc. SOURCE Karyopharm Therapeutics Inc. WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Drug Approval

100 Deals associated with Selinexor

External Link

KEGG	Wiki	ATC	Drug Bank
D11222	Selinexor	L01XX66	DB11942

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Follicular Lymphoma	Indonesia	Antengene Corp. Ltd.	05 Mar 2025
Refractory Multiple Myeloma	Macao	Antengene Corp. Ltd.	06 Dec 2023
Relapse multiple myeloma	Macao	Antengene Corp. Ltd.	06 Dec 2023
Diffuse large B-cell lymphoma recurrent	Israel	Karyopharm Therapeutics, Inc.	04 Feb 2021
Diffuse large B-cell lymphoma refractory	Israel	Karyopharm Therapeutics, Inc.	04 Feb 2021
Diffuse Large B-Cell Lymphoma	United States	Karyopharm Therapeutics, Inc.	22 Jun 2020
Multiple Myeloma	United States	Karyopharm Therapeutics, Inc.	03 Jul 2019

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Diffuse Large B-Cell Lymphoma	NDA/BLA	Malaysia	Antengene Corp. Ltd.	23 Dec 2022
Diffuse Large B-Cell Lymphoma	NDA/BLA	Thailand	Antengene Corp. Ltd.	23 Dec 2022
Diffuse Large B-Cell Lymphoma	NDA/BLA	Macao	Antengene Corp. Ltd.	23 Dec 2022
Multiple Myeloma	NDA/BLA	Macao	Antengene Corp. Ltd.	23 Dec 2022
Dedifferentiated Liposarcoma	Discovery	Israel	Karyopharm Therapeutics, Inc.	04 Jan 2016
Dedifferentiated Liposarcoma	Discovery	Italy	Karyopharm Therapeutics, Inc.	04 Jan 2016
Dedifferentiated Liposarcoma	Discovery	France	Karyopharm Therapeutics, Inc.	04 Jan 2016
Dedifferentiated Liposarcoma	Discovery	Germany	Karyopharm Therapeutics, Inc.	04 Jan 2016
Dedifferentiated Liposarcoma	Discovery	Belgium	Karyopharm Therapeutics, Inc.	04 Jan 2016
Dedifferentiated Liposarcoma	Discovery	Spain	Karyopharm Therapeutics, Inc.	04 Jan 2016

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03992339 (SEARCH study \| SEARCH, CTgov)	Phase 2	Diffuse Large B-Cell Lymphoma	60	ATG-010 60 mg, orally, twice weekly, each 4 week (28-day) a cycle	(xammhisbpp) = stxwjxrbpm mslzagoxwp (xyceggbnil, aloeryegcz - pmytbacylv) View more	-	07 Feb 2025
NCT02419495 (Pubmed \| Cancer Med) Manual	Phase 1	Advanced Renal Cell Carcinoma	29	Selinexor + Nivolumab	(emlvvnuype) = including 10% with hyponatremia, 7% with neutropenia, and 7% with thromboembolic events. svczfkrgup (owndurpjuu )	Positive	01 Feb 2025
				Selinexor + NivolumabNivolumab + Ipilimumab
NCT04421378 (XPORT-GBM-029 \| CTNI-18, CTgov)	Phase 1/2	Glioblastoma Multiforme \| Recurrent Glioblastoma	74	Selinexor (Arms A+B+C+D+E: Selinexor)	tzkfuahzfy(lkxauuarzr) = boynyxxigy eyszdseseu (oslfazksso, zbozflblmi - ihelhszckf)	-	16 Dec 2024
				Selinexor (Arm A: Selinexor + Radiation Therapy)	soayqwdlvu(cgigxsehqa) = pnbdvwwplm gpcmbwcacq (laobhcveok, kgshebjsgu - nwvhgmmofc) View more
ASH2024 Manual	Phase 2	Myelofibrosis	40	Selinexor + Ruxolitinib	(fpwfcksnrc) = soqmrasbgg orreekklyi (faaimxfkjw ) View more	Positive	09 Dec 2024
NCT04939142 (BENCH, ASH2024) Manual	Phase 3	Multiple Myeloma	154	Selinexor + Bortezomib + Dexamethasone	(ssmbucylhf) = omouerhtod bilghobhii (hlltjanprh ) View more	Positive	09 Dec 2024
				Bortezomib + Dexamethasone	(ssmbucylhf) = uvcfnorldb bilghobhii (hlltjanprh ) View more
NCT04425070 (TOUCH, ASH2024) Manual	Phase 1/2	Extranodal NK-T-Cell Lymphoma	17	Selinexor + Tislelizumab	(oycclfwwna) = cmacftoolj mnkixxsbhz (nwvtinnawj ) View more	Positive	09 Dec 2024
				Selinexor + Tislelizumab (CPIs exposed pts)	(oycclfwwna) = wjbtgiwkbg mnkixxsbhz (nwvtinnawj ) View more
ASH2024	Not Applicable	Multiple Myeloma	-	Selinexor/dexamethasone/pomalidomide	khgfnwbswd(gmfgfdbuuh) = Toxicity and tolerability were consistent with previous selinexor trials and generally manageable, with 11% of patients discontinuing treatment early due to adverse events. ihyzvnknkc (wookffmlpv )	-	08 Dec 2024
ChiCTR2200055486 (NEWS) Manual	Early Phase 1	Multiple Myeloma	19	塞利尼索+硼替佐米+沙利度胺+地塞米松	(dgwjfpcicp) = anqqvlsria hwclxyfnix (sgmuzpkujs ) View more	Positive	11 Nov 2024
NCT05432804 (CTNI-61, SNO2024)	Phase 1/2	Recurrent Glioblastoma MGMT promoter methylated	12	Selinexor 60mg	ipdxcvdfdc(kogtxmdmlp) = 42% pjaslzeujm (wtdajjhpfu ) View more	Positive	11 Nov 2024
NCT04216329 (CTgov)	Phase 1	Glioblastoma Multiforme \| Gliosarcoma \| Glioblastoma	11	Olanzapine+Temozolomide+Selinexor (All Participants)	ecabzkqpcu(nshqtyeapw) = lyoqxfbspb ouqnoxsqls (qzmpnnvueh, gstvidukoa - rulhhirhez)	-	15 Oct 2024
				Temozolomide+Selinexor (Dose Level 1: Selinexor 80mg on Weeks 1, 2, 4, 5 With Temozolomide & Radiation)	djujzaihtt(ifviriunea) = mcljbnmbxv tslkaloqgy (epubdzvvsa, vmddnuajuk - dsbzytzoum) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis